Cytosorbents Corp. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, filed on July 15, 2015, covers events occurring between July 9, 2015, and July 14, 2015. The filing primarily addresses Item 5.02 regarding the departure of a director, the appointment of a new director, and the execution of new executive employment agreements for the Company's President and CEO, CFO, and COO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms and board composition changes.
Material Changes and Executive Compensation
The Company entered into three-year executive employment agreements, retroactively effective as of January 1, 2015, with the following key terms:
- Phillip P. Chan (President and CEO): Annual base salary of $325,000 plus $12,000 for travel expenses. Severance for termination without Cause or Good Reason ranges from 6 to 12 months of salary. Change in Control severance is 12 months of salary.
- Kathleen P. Bloch (CFO): Annual base salary of $235,000. Severance for termination without Cause or Good Reason ranges from 6 to 12 months of salary. Change in Control severance is 9 months of salary.
- Vincent Capponi (COO): Annual base salary of $270,000. Severance for termination without Cause or Good Reason ranges from 6 to 12 months of salary. Change in Control severance ranges from 6 to 12 months of salary.
All agreements include provisions for COBRA premium payments, acceleration of stock option vesting upon qualifying termination, and tax gross-ups for excise taxes under IRC Section 4999.
Board of Directors Changes
- Resignation: James T. Gunton resigned from the Board and all committees effective July 9, 2015. The resignation was not due to any disagreement with the Company.
- Appointment: Michael G. Bator was appointed to the Board and the Compensation Committee effective July 14, 2015.
- Director Compensation: Mr. Bator will receive an annual retainer of $10,000 for Board service and $3,000 for Compensation Committee service. He was granted an initial option to purchase 6,000 shares at an exercise price of $6.65, vesting 25% quarterly.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on business outlook, specific risks, or contingencies beyond the standard terms of the employment agreements. The agreements outline financial contingencies related to termination events and Change in Control scenarios.
Investor Verification Checklist
- Verify the total annual fixed compensation obligation for the three new executive agreements ($830,000 combined base salary).
- Review the full text of Exhibits 10.1, 10.2, and 10.3 to understand specific definitions of "Cause" and "Good Reason" which trigger severance.
- Assess the impact of the new director's stock option grant (6,000 shares at $6.65) on potential dilution.
- Confirm the Company's current cash position to ensure it can meet potential severance obligations in the event of a Change in Control or executive departure.